Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial

BACKGROUND: Bisphosphonates are the standard of care for reducing the risk of skeletal-related events in patients with bone lesions from multiple myeloma. The MRC Myeloma IX study was designed to compare the effects of zoledronic acid versus clodronic acid in newly diagnosed patients with multiple m...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Morgan, Gareth J, Child, J Anthony, Gregory, Walter M, Szubert, Alex J, Cocks, Kim, Bell, Sue E, Navarro-Coy, Nuria, Drayson, Mark T, Owen, Roger G, Feyler, Sylvia, Ashcroft, A John, Ross, Fiona M, Byrne, Jennifer, Roddie, Huw, Rudin, Claudius, Cook, Gordon, Jackson, Graham H, Wu, Ping, Davies, Faith E
Formato: Artigo
Idioma:Inglês
Publicado em: Lancet Pub. Group 2011
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3148431/
https://ncbi.nlm.nih.gov/pubmed/21771568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(11)70157-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados